| Insight Imaging Reports Results for the Third Quarter Fiscal 2010 (Business Wire) LAKE FOREST, Calif.----InSight Health Services Holdings Corp. today announced its financial results for the third quarter ended March 31, 2010. us.rd.yahoo.com |
Vivus, Arena and Orexigen Investors All Worried About Qnexa FDA Panel Review Joseph Krueger submits: This week is a critical time period for Vivus (VVUS) investors, but it should also be interesting for Arena Pharmaceuticals (ARNA) and Orexigen (OREX) investors, as the three companies all have near term FDA panel reviews and PDUFA dates for their obesity drugs. Vivus’ New Drug Application (NDA) for their weight loss drug, Qnexa, is up for review by the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on July 12 or July 13 (per Bloomberg reported by theflyonthewall.com). This review by outside advisory panelists will foreshadow the likelihood of FDA approval for Qnexa, as the FDA’s actions generally follow with the reviewers opinion. The target date for the FDA to complete its review of the Qnexa NDA is October 28, 2010.Qnexa is a combination of two different generic drugs: Phentermine (formally marketed as Fastin and many other names) and Topiramate (formally marketed as Topamax). Phentermine is an appetite suppressant and stimulant similar to amphetamines. Topiramate is an anticonvulsant drug (designed to stop seizures) and is available in the U.S. in several different formulations generically. Phentermine has typically always been used as an appetite suppressant. Topiramate has been used to treat many different central nervous system (CNS) disorders, including seizure disorders such as epilepsy, biopolar disorder, tremors, obsessive compulsive disorders, behavioral obesity, drug, alcoholism, and smoking cessation. Complete Story » seekingalpha.com |
Enzo Biochem's Clinical Labs Unit Named a Participant in Empire BlueCross BlueShield Provider Network (Business Wire) NEW YORK----Enzo Biochem Inc.’s wholly-owned subsidiary, Enzo Clinical Labs, Inc., and Empire BlueCross BlueShield, the largest health insurer in New York State, today jointly announced that effective August 1, 2010 Enzo Clinical Labs will be a participating laboratory in the Empire provider network for the metropolitan New York area. us.rd.yahoo.com |
InSight Imaging Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2010 [Business Wire] - LAKE FOREST, Calif.----InSight Health Services Holdings Corp. today announced its financial results for the fourth quarter and fiscal year ended June 30, 2010. us.rd.yahoo.com |
Long-Term-Care Insurance Premiums Soar People with long-term-care insurance polices are getting hit with a new round of steep premium increases. But there are options that can help both existing policyholders and new buyers cut some of the costs. online.wsj.com |